Variations in plasma concentration in patients with non-small cell lung cancer on fixed-dose erlotinib
Phase 1
- Conditions
- ung cancerTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-004350-29-DK
- Lead Sponsor
- herlev hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
lung cancer
taking erlotinib
informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50
Exclusion Criteria
none
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method